Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS)
NCT ID: NCT02391064
Last Updated: 2018-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
421 participants
INTERVENTIONAL
2015-02-17
2018-02-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Purpose: to establish the screening value of a brief computerized cognitive assessment (BCCAMS) combining the computerized speed cognitive test (CSCT) and a new computerized episodic visual memory test (CEVMT) in French-speaking patients with multiple sclerosis as compared to a reference battery (MACFIMS).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Depression and Facial Identity Recognition Abilities in Patients With Multiple Sclerosis
NCT02468765
Bayer/Cognitive Assessments With Multiple Sclerosis Subjects
NCT00888277
Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients
NCT02290587
Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis
NCT04756700
CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis
NCT05671055
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient
MS Relapsing-remitting under interferon beta-1b treatment in inclusion, Secondary progressive and Primary progressive MS forms
Cognitive evaluation
* Questionnaires for assessment of confounding factors
* Cognitive evaluation
* Walking tests and 9 Hole Peg Test
Expanded Disability Status Scale (EDSS) score
\- EDSS score
Control
healthy subject
Cognitive evaluation
* Questionnaires for assessment of confounding factors
* Cognitive evaluation
* Walking tests and 9 Hole Peg Test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cognitive evaluation
* Questionnaires for assessment of confounding factors
* Cognitive evaluation
* Walking tests and 9 Hole Peg Test
Expanded Disability Status Scale (EDSS) score
\- EDSS score
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18-64 years
* Francophone
* MS Relapsing-remitting under interferon beta-1b treatment in inclusion, Secondary progressive and Primary progressive MS forms
* Having signed an informed consent (later than the day of inclusion and before any examination required by research)
* Being affiliated to health insurance
Controls:
* Aged 18-64 years
* Francophone
* Having signed an informed consent (later than the day of inclusion and before any examination required by research)
* Being affiliated to health insurance
Exclusion Criteria
* Other neurological diseases with impact on cognitive functions.
* Severe psychiatric disease or severe depression.
* Current Dependence on alcohol or drugs.
* Modification or stop of psychotropic treatment in less than a month.
* Modification of MS treatment in less than a month.
* Visual, visual-motor and / or motor impairments excluding the ability to perform cognitive tests.
* Pregnant
Controls:
* Neurologic disease and known chronic systemic with impact on cognitive functions.
* Severe psychiatric disease or severe depression.
* Current Dependence on alcohol or drugs.
* Psychotropic treatment
* Cognitive complaint
* Prior cognitive testing with the same tests less than one year.
* Pregnant
18 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
University Hospital, Bordeaux
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Bordeaux
Bordeaux, , France
CHU de Caen
Caen, , France
CHU de Clermont-Ferrand
Clermont-Ferrand, , France
Hôpital du Bocage
Dijon, , France
CH de Dunkerque
Dunkirk, , France
Centre Hospitalier Saint Vincent de Paul
Lille, , France
Hôpital Roger Salengro
Lille, , France
CHU de Marseille
Marseille, , France
CHU Montpellier
Montpellier, , France
CHU de Nancy
Nancy, , France
CHU de Nice
Nice, , France
Hôpital Tenon
Paris, , France
Hôpital de Poissy Saint Germain
Poissy, , France
CHU de Reims
Reims, , France
CHU de Strasbourg
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUBX 2013/23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.